Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3149-3155

  Kempker, Russell R ^a   Barth, Aline B ^b   Vashakidze, Sergo ^c   Nikolaishvili, Ketino ^c   Sabulua, Irina ^c   Tukvadze, Nestani ^c   Bablishvili, Nino ^c   Gogishvili, Shota ^c   Singh, Ravi Shankar P ^b   Guarner, Jeannette ^a   Derendorf, Hartmut ^b   Peloquin, Charles A ^b   Blumberg, Henry M ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c National Centre for Tuberculosis and Lung Disease   (Georgia)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; EX VIVO STUDY; FEMALE; GEORGIA (REPUBLIC); HUMAN; LIQUID; LUNG SURGERY; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; BLOOD; CLINICAL TRIAL; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; LEVOFLOXACIN; MALE; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84929630587     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00379-15     Document Type: Article

References (37)

1. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. 2014. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2:321-338. http://dx.doi.org/10.1016/S2213-2600(14)70031-1.
2. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. 2009. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9:153-161. http://dx.doi.org/10.1016/S1473-3099(09)70041-6.
3. WHO. 2013. Global tuberculosis report. WHO/HTM/20131. WHO, Geneva, Switzerland.
4. Dartois V, Barry CE. 2010. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 5:96-114. http://dx.doi.org/10.2174/157488410791110797.
5. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 204:1951-1959. http://dx.doi.org/10.1093/infdis/jir658.
6. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464-1473. http://dx.doi.org/10.1093/infdis/jit352.
7. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 48:1685-1694. http://dx.doi.org/10.1086/599040.
8. Mpagama SG, Ndusilo N, Stroup S, Kumburu H, Peloquin CA, Gratz J, Houpt ER, Kibiki GS, Heysell SK. 2014. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 58:782-788. http://dx.doi.org/10.1128/AAC.01549-13.
9. Akkerman OW, van Altena R, Klinkenberg T, Brouwers AH, Bongaerts AH, van der Werf TS, Alffenaar JW. 2013. Drug concentration in lung tissue in multidrug-resistant tuberculosis. Eur Respir J 42:1750-1752. http://dx.doi.org/10.1183/09031936.00047413.
10. Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM. 2012. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 12:157-166. http://dx.doi.org/10.1016/S1473-3099(11)70244-4.
11. Xu HB, Jiang RH, Li L. 2011. Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. J Antimicrob Chemother 66:1687-1695. http://dx.doi.org/10.1093/jac/dkr210.
12. Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, Blumberg HM, Vashakidze S. 2012. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis 54:e51-54. http://dx.doi.org/10.1093/cid/cir904.
13. Vashakidze S, Gogishvili S, Nikolaishvili K, Dzidzikashvili N, Tukvadze N, Blumberg HM, Kempker RR. 2013. Favorable outcomes for multidrug and extensively drug resistant tuberculosis patients undergoing surgery. Ann Thorac Surg 95:1892-1898. http://dx.doi.org/10.1016/j.athoracsur.2013.03.067.
14. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL, Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. 2007. AAPS-FDA Workshop white paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol 47:589-603. http://dx.doi.org/10.1177/0091270006299091.
15. Azeredo FJ, Dalla Costa T, Derendorf H. 2014. Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions. Clin Pharmacokinet 53:205-212. http://dx.doi.org/10.1007/s40262-014-0131-8.
16. WHO. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. WHO, Geneva, Switzerland.
17. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. 2006. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 10:605-612.
18. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 52:852-857. http://dx.doi.org/10.1128/AAC.01036-07.
19. Stenken JA. 1999. Methods and issues in microdialysis calibration. Anal Chim Acta 379:337-358. http://dx.doi.org/10.1016/S0003-2670(98)00598-4.
20. Lonnroth P, Jansson PA, Smith U. 1987. A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol 253:E228-231.
21. Tukvadze N, Kempker RR, Kalandadze I, Kurbatova E, Leonard MK, Apsindzelashvili R, Bablishvili N, Kipiani M, Blumberg HM. 2012. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS One 7:e31563. http://dx.doi.org/10.1371/journal.pone.0031563.
22. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, Spector S, Roscigno G, Nkengasong J. 2011. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 24:314-350. http://dx.doi.org/10.1128/CMR.00059-10.
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377-381. http://dx.doi.org/10.1016/j.jbi.2008.08.010.
24. Davis SL, Neuhauser MM, McKinnon PS. 2005. Quinolones, p 337-366. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD (ed), Antimicrobial chemotherapy and vaccines, 2nd ed, vol II. Antimicrobial agents. Esun Technologies, LLC, Pittsburgh, PA.
25. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Pena J, Perez-Guzman C, Quelapio MI, Ponce-de-Leon A, et al. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 9:e1001300. http://dx.doi.org/10.1371/journal.pmed.1001300.
26. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, Wells CD, Leimane V. 2006. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144:650-659. http://dx.doi.org/10.7326/0003-4819-144-9-200605020-00008.
27. Hamilton CD, Stout JE, Goodman PC, Mosher A, Menzies R, Schluger NW, Khan A, Johnson JL, Vernon AN. 2008. The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. Int J Tuberc Lung Dis 12:1059-1064.
28. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, Mathema B, Ramaswamy SV, Walther G, Steyn LM, Barry CE, III, Bekker LG. 2003. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 71: 7099-7108. http://dx.doi.org/10.1128/IAI.71.12.7099-7108.2003.
29. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. 2007. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 45:1290-1295. http://dx.doi.org/10.1086/522537.
30. Torun T, Tahaoglu K, Ozmen I, Sevim T, Atac G, Kir A, Gungor G, Bolukbasi Y, Maden E. 2007. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 11:979-985.
31. Kislitsyna NA. 1985. Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients. Probl Tuberk 1985:55-57. (In Russian.)
32. Kislitsyna NA, Kotova NI. 1980. Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations. Probl Tuberk 1980:63-65. (In Russian.)
33. Chierakul N, Klomsawat D, Chulavatnatol S, Chindavijak B. 2001. Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis. Int J Tuberc Lung Dis 5:278-282.
34. Dhanani J, Roberts JA, Chew M, Lipman J, Boots RJ, Paterson DL, Fraser JF. 2010. Antimicrobial chemotherapy and lung microdialysis: a review. Int J Antimicrob Agents 36:491-500. http://dx.doi.org/10.1016/j.ijantimicag.2010.08.013.
35. Lindenmann J, Kugler SA, Matzi V, Porubsky C, Maier A, Dittrich P, Graninger W, Smolle-Juttner FM, Joukhadar C. 2011. High extracellular levels of cefpirome in unaffected and infected lung tissue of patients. J Antimicrob Chemother 66:160-164. http://dx.doi.org/10.1093/jac/dkq413.
36. Matzi V, Lindenmann J, Porubsky C, Kugler SA, Maier A, Dittrich P, Smolle-Juttner FM, Joukhadar C. 2010. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 65: 995-998. http://dx.doi.org/10.1093/jac/dkq070.
37. Prideaux B, Dartois V, Staab D, Weiner DM, Goh A, Via LE, Barry CE, III, Stoeckli M. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 83:2112-2118. http://dx.doi.org/10.1021/ac1029049.